Schlussel's Ratings

BUY SCLP by Schlussel on 22 Feb 2014 13:19

Price at rating: 33.50, now:

The FDA's recent granting of Orphan Drug Designation to Scancell's lead cancer vaccine, SCIB1, massively increases the likelihood of a licensing deal in the near future.

Score: 78.75

BUY SCLP by Schlussel on 10 Jan 2014 08:05

Price at rating: 29.77, now:

Scancell is expected to conclude licensing deals on both of its two cancer vaccine platforms. The shares will rise steeply when the first of these deals is announced. Getting in ahead of these deals while the shares are cheap makes a lot of sense.

Score: 100.00

BUY SAR by Schlussel on 25 Oct 2013 06:00

Price at rating: 0.82, now:

Score: 60.00

BUY SCLP by Schlussel on 25 Oct 2013 04:39

Price at rating: 30.88, now:

Score: 61.25

BUY SAR by Schlussel on 23 Oct 2013 21:39

Price at rating: 0.81, now:

Sareum now has excellent prospects for funding their pipeline of preclinical molecules following their recent deal. As the market for kinase inhibitors gets ever hotter expect this company to be the focus of further industry attention.

Score: 97.50

BUY SCLP by Schlussel on 23 Oct 2013 20:20

Price at rating: 30.80, now:

Score: 85.00

BUY SCLP by Schlussel on 22 Oct 2013 19:32

Price at rating: 30.22, now:

Score: 97.50

BUY SAR by Schlussel on 24 Sep 2013 09:02

Price at rating: 0.98, now:

Money at last for Sareum. All good things to those that wait. Kinase inhibitors are big money nowadays with commercial versions adding as much as $5 billion to an acquisition deal e.g., Onyx. Sareum has a great development tie up with SRI international as well so expect some fireworks ahead share-price-wise. r Strong BUY

Score: 3.75